Click here for slides on this topic


Pioglitazone

(ACTOS) An oral antidiabetic agent of the thiazolidinedione class that is used to treat type 2 diabetes.


The following content matched the glossary term: Pioglitazone

CompanionSetType2DiabetesMedications

Top

Patient education companion set featuring handouts on DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and medications used to treat type 2 diabetes (English and Spanish)

Medications Used To Treat Type 2 Diabetes

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose.

Managing the Patient With Type 2 Diabetes and Heart Failure

Top

.style1 FONT FAMILY Arial, Helvetica, sans serif COLOR #004685

Medicamentos para el tratamiento de la diabetes tipo 2

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose—in Spanish.

NDEI.org Expert Commentary on Type 2 Diabetes Treatment Trends from Vivian Fonseca, MD

Top

NDEI Education Council Member Vivian A. Fonseca, MD, comments on a study exploring type 2 diabetes treatment trends in the U.S.: “Clinicians could use these data to determine whether their own prescribing has changed in line with national trends”

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012

Top

Exclusive! Expert commentary from Vivian A. Fonseca, MD, on this study. Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC. Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. Diabetes Care. 2014;37:985-992.

ADA 2016 Type 2 Diabetes Pharmacologic Therapy

Top

Pharmacologic treatment options for type 2 diabetes from the 2016 ADA guidelines

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin

Top

Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475-483. A recent position statement from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) cites metformin as the optimal first-line drug for diabetes treatment. However, the statement acknowledges that limited data exist regarding treatments to be used beyond metformin.

β-cell function preservation after 3.5 years of intensive diabetes therapy

Top

Harrison LB, Adams Huet B, Raskin P, Lingvay I. Beta cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care. 2012;35(7):1406-1412. To assess beta-cell function preservation after 3.5 years of intensive therapy with insulin plus metformin (INS group) versus triple oral therapy (TOT group) with metformin, glyburide, and pioglitazone.

Meta-analysis: DPP-4 Inhibitors for Type 2 Diabetes

Top

Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Meta-analysis: DPP-4 Inhibitors for Type 2 Diabetes. BMJ. 2012 Mar 12;344:e1369. doi: 10.1136/bmj.e1369. Karagiannis and colleagues conducted a systematic review and meta-analysis of 27 studies to evaluate the efficacy of DPP-4 inhibitors for treatment of type 2 diabetes when compared with other antihyperglycemic therapies.

1 2 3 4 5 6 7 8 9 10  ... Next 

Slide Library Results

Search Results for: Pioglitazone Slides Found: 68
Pioglitazone: Dosing Recommendations
Effect of Pioglitazone Monotherapy on Lipid Levels
Effect of Pioglitazone on Lipid Levels
Thiazolidinediones and Adipose Tissue Redistribution
Effect of Pioglitazone Monotherapy on Lipid Levels
Effect of Pioglitazone on Lipid Levels
Effect of Pioglitazone on Insulin Resistance: HOMA-IR
Effect of Pioglitazone on B-Cell Function: HOMA bCF
Effect of Early Thiazolidinedione Therapy on A1C Levels
Effect of Early Thiazolidinedione Therapy on C-Peptide Levels
Effect of Early Thiazolidinedione Therapy on Diabetes Onset
Pioglitazone Decreases Carotid IMT Independent of Glycemic Control in Patients With Type 2 Diabetes
Adverse Events Associated With Thiazolidinedione Treatment
GLAI: Enrollment Criteria
GLAI: Comparison of Pioglitazone vs Rosiglitazone on Glycemic Control
Pioglitazone Reduces VLDL-TG Levels by Increasing LPL-Mediated Lipolysis
PROactive: Objective/Endpoints
PROactive: Time to Primary Composite Endpoint
PROactive: Time to Main Secondary Composite Endpoint (Death, Nonfatal MI, or Stroke)
PROactive: Heart Failure Events
Comparison of Diabetes Rates Across PIPOD and TRIPOD
Sitagliptin Improves Glycemic Control in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
Vildagliptin + Pioglitazone Improves A1C in Patients Not Controlled With Thiazolidinedione Monotherapy
Vildagliptin + Pioglitazone Increases Beta-Cell Insulin Secretory Rate
Thiazolidinediones vs Insulin: Comparison of Diabetes-Related Healthcare Utilization and Costs Over 12 Months
Sitagliptin Improves A1C in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
Sitagliptin Reduces FPG in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
Effect of Exenatide + TZD on Blood Glucose in Patients With Type 2 Diabetes
Effect of Exenatide + TZD on Body Weight in Patients With Type 2 Diabetes
Cardiovascular Impact of Pioglitazone Therapy: A Meta-analysis
Duration of TZD Therapy Prior to Onset of Heart Failure
Dose and Duration of TZD Therapy Prior to Onset of Heart Failure
Pioglitazone Reduces the Risk of Hospitalization for AMI
GLAI: Comparison of TZDs on Lipoprotein Subclass Particle Size
PROactive 10 Substudy: Time to CV Death, Nonfatal MIa, Nonfatal Stroke
PROactive 10 Substudy: Time to All-Cause Mortality, Nonfatal MIa, Nonfatal Stroke, or ACS
Efficacy of Pioglitazone Plus Sibutramine in Metformin-Intolerant vs Metformin-Tolerant Obese Subjects With Type 2 Diabetes
PROactive 10 Substudy: Time to First Event from MACE Endpoint
Vildagliptin vs Metformin: A1C
Indian Diabetes Prevention Programme-2: Study Design
Indian Diabetes Prevention Programme-2: Results
Risk of Cardiovascular Events During Treatment with Pioglitazone or Rosiglitazone: Design
Risk of Cardiovascular Events During Treatment with Pioglitazone or Rosiglitazone: Composite Outcome
DURATION-4: Design
DURATION-4: Mean Change in A1C from Baseline to Week 26
DURATION-4: Additional Outcomes
DURATION-4: Most Common Adverse Events
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Change in A1C from Baseline
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Adverse Events and All-Cause Mortality
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: Design
Efficacy of Twice-Daily Exenatide Added to Basal Insulin for A1C Reduction: Design
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo : A1C Reduction at 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Target A1C Levels at 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Body Weight 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Hypoglycemia at 30 Wks
Twice-Daily Exenatide Vs Placebo Added to Basal Insulin: Adverse Events
US Trends in Type 2 Diabetes Treatment, 1997-2012: Medication Classes
GLP-1 Receptor Agonists A1C Type 2 Diabetes | NDEI
TECOS Sitagliptin Cardiovascular Safety High-Risk Type 2 Diabetes DPP-4 | NDEI
TECOS Cardiovascular Outcomes Sitagliptin DPP-4 | NDEI
TECOS Heart Failure Sitaliptin DPP-4 CV Safety | NDEI
TECOS Sitagliptin DPP-4 Inhibitor Pancreatitis Hypoglycemia | NDEI
TECOS Sitagliptin A1C Efficacy DPP-4 Inhibitor CV Safety | NDEI
Sitagliptin Not Associated With Heart Failure in TECOS Type 2 Diabetes | NDEI
IRIS Design Pioglitazone Effect on Cerebrovascular Disease Stroke PPT | NDEI
IRIS Pioglitazone Lowers Risk for Stroke and TIA Vs Placebo PPT | NDEI
IRIS Pioglitazone Lowers Rate of Progression to Diabetes Vs Placebo | NDEI
IRIS Safety of Pioglitazone Vs Placebo After Stroke or TIA PPT | NDEI